Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
Market Cap 82.38M P/E - EPS this Y 2.20% Ern Qtrly Grth -
Income -15.07M Forward P/E -6.54 EPS next Y 16.30% 50D Avg Chg 1.00%
Sales - PEG - EPS past 5Y - 200D Avg Chg 1.00%
Dividend N/A Price/Book N/A EPS next 5Y - 52W High Chg -11.00%
Recommedations 2.00 Quick Ratio 1.97 Shares Outstanding 13.77M 52W Low Chg 11.00%
Insider Own 47.16% ROA -72.74% Shares Float 6.34M Beta -
Inst Own 12.19% ROE -147.23% Shares Shorted/Prior 26.69K/19.84K Price 6.02
Gross Margin - Profit Margin - Avg. Volume 121,382 Target Price 14.33
Oper. Margin - Earnings Date - Volume 8,515 Change 0.00%
About Intensity Therapeutics, Inc.

Intensity Therapeutics, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of cancer drugs in the United States. Its lead product candidate includes INT230-6, which is in human clinical studies for the treatment of refractory solid tumors, such as soft tissue sarcoma which is in phase 3 trails; and neoadjuvant and metastatic triple negative breast cancer which is in Phase 2 clinical trials. The company was incorporated in 2012 and is headquartered in Shelton, Connecticut.

Intensity Therapeutics, Inc. News
12/13/24 Intensity Therapeutics reports positive results of INT230-6 in breast cancer
12/12/24 Intensity Therapeutics Says Cancer Drug Candidate Shows Benefits in Phase 2 Trial
12/12/24 Intensity Therapeutics, Inc. and The Swiss Group for Clinical Cancer Research SAKK Present Phase 2 Data in Presurgical Breast Cancer from the completed INVINCIBLE-2 Study, and an Overview of the Ongoing Randomized, Presurgical Triple Negative Breast Cancer Phase 2 Clinical Trial, INVINCIBLE-4 (SAKK 66/22), at the 2024 San Antonio Breast Cancer Symposium (SABCS)
11/21/24 Intensity Therapeutics, Inc. Announces Pricing of $3 Million Registered Direct Offering and Concurrent Private Placement
11/18/24 Intensity Therapeutics Presents INT230-6 Phase 1/2 Data in Sarcoma and an Overview of its Ongoing Global Randomized Phase 3 Sarcoma Trial ("INVINCIBLE-3 Study") in a Late-Breaking Session at the 2024 Annual Connective Tissue Oncology Society Meeting (CTOS)
11/13/24 Intensity Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update
11/13/24 3 US Penny Stocks With Market Caps Under $200M To Watch
11/08/24 Intensity Therapeutics Selected for Oral Podium Presentation in a Late-Breaking Session at the 2024 Annual Connective Tissue Oncology Society (Sarcomas) Meeting
10/31/24 Intensity Therapeutics, Inc. and The Swiss Group for Clinical Cancer Research SAKK Announce the First Patient Dosed in the Randomized, Presurgical Triple Negative Breast Cancer Phase 2 Clinical Trial (INVINCIBLE-4 / SAKK 66/22)
09/04/24 Intensity Therapeutics to Present at the H.C. Wainwright 26th Annual Global Investment Conference
08/08/24 Intensity Therapeutics Reports Second Quarter 2024 Financial Results and Provides Corporate Update
07/09/24 Intensity Therapeutics, Inc. Announces First Patient Dosed in its Global Randomized, Phase 3 Study (INVINCIBLE-3) in Metastatic Soft Tissue Sarcoma
06/06/24 Will Intensity Therapeutics (NASDAQ:INTS) Spend Its Cash Wisely?
05/15/24 Intensity Therapeutics, Inc. Announces the Appointment of Thomas Dubin to Its Board of Directors
05/10/24 Intensity Therapeutics, Inc. and The Swiss Group for Clinical Cancer Research SAKK Sign a Collaboration Agreement to Conduct a Phase 2 Randomized, Clinical Trial in Early-Stage Breast Cancer in Europe for INT230-6, Intensity's Lead Drug Candidate
05/09/24 Intensity Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update
04/02/24 Intensity Therapeutics to Participate in the LD Micro Invitational XIV Conference April 8 - 9, 2024
07:01 AM Portage Biotech Completes Monetization of Intensity Therapeutics (INTS) shares
03/14/24 Intensity Therapeutics Reports Full Year 2023 Financial Results and Provides Corporate Update
03/14/24 Intensity Therapeutics to Participate in the 36th Annual Roth Conference March 17 to 19, 2024
INTS Chatroom

User Image GTM86 Posted - 5 days ago

$INTS intense trash

User Image mikedumbledar Posted - 5 days ago

$INTS armistice. just stay away from any biotech owned by armistice.

User Image GTM86 Posted - 6 days ago

$INTS nothing intense about this price action

User Image mrea0 Posted - 1 week ago

$INTS

User Image DaNiuBiJiaoLan Posted - 1 week ago

$INTS why that price keep going down, with the good news... Sigh

User Image mrea0 Posted - 1 week ago

$CADL some attention for this pharma $INTS, they just complet phase 2 for breast cancer with success , rated strong buy with 16$ for price target https://www.tipranks.com/news/the-fly/intensity-therapeutics-reports-positive-results-of-int230-6-in-breast-cancer?utm_source=webullapp.com&utm_medium=referral

User Image mrea0 Posted - 1 week ago

$DBVT some attention for this pharma $INTS, they just complet phase 2 for breast cancer with success https://www.tipranks.com/news/the-fly/intensity-therapeutics-reports-positive-results-of-int230-6-in-breast-cancer?utm_source=webullapp.com&utm_medium=referral

User Image mrea0 Posted - 1 week ago

$CPIX some attention for this pharma $INTS, they just complet phase 2 for breast cancer with success https://www.tipranks.com/news/the-fly/intensity-therapeutics-reports-positive-results-of-int230-6-in-breast-cancer?utm_source=webullapp.com&utm_medium=referral

User Image Celz Posted - 1 week ago

$INTS this stock with this news deserve +1000% but market like Chinese scam

User Image _www_larval_com_ Posted - 1 week ago

$INTS has reversed 9% higher to -15% (~210Kv) a few minutes ago, follow for more volatility.

User Image arrotrader Posted - 1 week ago

$INTS

User Image _www_larval_com_ Posted - 1 week ago

$AMPG 18%[32%] $HIMX 10%[16%] $LNKS 9%[15%] $INTS -8%[-10%] $BZFD -8%[-11%] most notable movement within the first minutes of trading.

User Image TA_Kongen Posted - 1 week ago

$INTS Meh, just had offering. 2.45 and 2.95.

User Image DARKP00L Posted - 1 week ago

$INTS ﹩3.09 - Intensity Therapeutics, Inc. and The Swiss Group for Clinical Cancer Research SAKK Present Phase 2 Data in Presurgical Breast Cancer from the completed INVINCIBLE-2 Study, and an Overview of the Ongoing Randomized, Presurgical Triple Negative Breast Cancer Phase 2 Clinical Trial, INVINCIBLE-4 (SAKK 66/22), at the 2024 San Antonio Breast Cancer Symposium (SABCS) #pennystock #stockmarket #lowfloat #stockstotrade #stockscanner #tradinginsights #NYSE #darkpools

User Image Dareing Posted - 1 week ago

$INTS insane news this will go crazy today

User Image NVDAMillionaire Posted - 2 weeks ago

$INTS Intensity Therapeutics (NASDAQ:INTS): Building a Formidable Pipeline to Tackle Solid Tumors https://beyondspx.com/article/intensity-therapeutics-nasdaqints-building-a-formidable-pipeline-to-tackle-solid-tumors

User Image OpenOutcrier Posted - 1 month ago

$INTS (-5.1% pre) Intensity Therapeutics (INTS) Announces Pricing of $3 Million Registered Direct Offering and Concurrent Private Placement - SI https://ooc.bz/l/48947

User Image Stmkr Posted - 1 month ago

$INTS Has the company discussed how it plans to fung ongoing/planned trials??

User Image Stmkr Posted - 1 month ago

$INTS Just 3M?? Less even than the operating expenses of a single quarter

User Image justiceforb_85 Posted - 1 month ago

$INTS $XBI excellent data for INT230-6 in significantly improving survival across various sarcoma subtypes. https://ir.intensitytherapeutics.com/news-events/press-releases/detail/92/intensity-therapeutics-presents-int230-6-phase-12-data-in

User Image donutfish Posted - 1 month ago

$INTS Anyone see the CTOS presentation they did?

User Image Powderranger Posted - 1 month ago

$INTS sleeping giant

User Image justiceforb_85 Posted - 1 month ago

$INTS would be great to have INT230-6 as an option for STS and TNBC. https://www.curetoday.com/view/first-patient-dosed-in-trial-of-int230-6-for-triple-negative-breast-cancer

User Image justiceforb_85 Posted - 1 month ago

$INTS $XBI looking forward to the news. https://ir.intensitytherapeutics.com/news-events/press-releases/detail/90/intensity-therapeutics-selected-for-oral-podium

User Image IN0V8 Posted - 10/31/24

$INTS Watch H.C. Wainwright initiates coverage with buy rating H.C. Wainwright initiates coverage with target $5

User Image Thestocktraderhubzee Posted - 10/31/24

$INTS Intensity Therapeutics And The Swiss Group For Clinical Cancer Research SAKK Dosed First Patient In Randomized, Presurgical Triple Negative Breast Cancer Phase 2 Clinical Trial

User Image Ianwalsh15 Posted - 2 months ago

$INTS

User Image UPupANDaway2020 Posted - 3 months ago

$INTS log in and register…listen to the audio! Going to Phase 3 Trial. https://journey.ct.events/view/ef21791d-dcfa-4af5-a93b-8ba594c598c6

User Image justiceforb_85 Posted - 4 months ago

$INTS $XBI hoping for positive news on trial for soft tissue sarcoma and TNBC.

User Image ReadyMate Posted - 4 months ago

$PRTG $INTS $BHVN That should have read ‘sad’ instead of ‘sas’

Analyst Ratings
Benchmark Speculative Buy Jul 11, 24
Benchmark Speculative Buy May 16, 24
Benchmark Speculative Buy Mar 21, 24
Benchmark Speculative Buy Nov 14, 23
Benchmark Speculative Buy Aug 24, 23
Benchmark Speculative Buy Jul 18, 23